Tumor News and Research

RSS

Study opens new avenues of research to improve care for patients with COPD

Researchers from Boston University School of Medicine have pinpointed a genetic signature for chronic obstructive pulmonary disease from airway cells harvested utilizing a minimally invasive procedure.

12 Apr 2013

Androgen receptors found to be a potential target in breast cancer

Estrogen and progesterone receptors, and the gene HER2 - these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.

11 Apr 2013

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.

11 Apr 2013

New research reveals how autophagy keeps neural stem cells to replace damaged brain, nerve cells

Deep inside your brain, a legion of stem cells lies ready to turn into new brain and nerve cells whenever and wherever you need them most. While they wait, they keep themselves in a state of perpetual readiness - poised to become any type of nerve cell you might need as your cells age or get damaged.

11 Apr 2013

$Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients$

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.

11 Apr 2013

Cellectis CanCELL cell lines enable drug positioning in cancer pathways

CanCELL cell lines are featuring gene knock-outs of the major cancer relevant oncogenes and tumor suppressor genes. This new product line answers identified market needs in oncology research and drug discovery.

11 Apr 2013

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

Researchers may have discovered a more accurate way to predict how long patients with the deadliest form of brain cancer will live, according to an analysis by researchers from the University of Alabama at Birmingham published today in the journal PLOS ONE.

11 Apr 2013

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.

11 Apr 2013

New research finds HPV plays role in lung cancer in some patients

A common virus known to cause cervical and head and neck cancers may also trigger some cases of lung cancer, according to new research presented by Fox Chase Cancer Center at the AACR Annual Meeting 2013 on Wednesday, April 10.

11 Apr 2013

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

DelMar Pharmaceuticals, Inc. today announced additional positive interim data from an ongoing Phase I/II clinical trial of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) or progressive secondary brain tumor.

11 Apr 2013

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia.

11 Apr 2013

Updated clinical data from phase I study of Ensituximab presented at AACR meeting

Precision Biologics announced today that in conjunction with researchers from Precsion Biologics , Johns Hopkins Medical Center and Duke University Medical Center presented updated clinical data from the phase I study of Ensituximab, a novel therapeutic antibody to treat pancreas and colorectal cancers

11 Apr 2013

Data on PV-10 combination therapy presented at AACR Annual Meeting

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented data on PV-10 combination therapy today at the American Association for Cancer Research Annual Meeting in Washington, DC.

11 Apr 2013

Research opens new avenue for treatment of melanoma

For the first time, scientists have demonstrated the mechanism of action of gossypin, a naturally-occurring substance found in fruits and vegetables, as a treatment for melanoma, which causes the majority of deaths from skin cancer.

11 Apr 2013

Study shows hsa-miR-146a overexpressed in most metastatic tumors

In order to kill, bladder cancer must metastasize, most commonly to the lung - what are the differences between bladder cancers that do and do not make this deadly transition? Research presented by the Director of the University of Colorado Cancer Center at the AACR Annual Meeting 2013 shows that one big difference is a little molecule known as hsa-miR-146a.

11 Apr 2013

Preclinical study of cabozantinib in prostate cancer bone metastasis model presented at AACR meeting

Exelixis, Inc. announced the presentation of preclinical data that provide insight into the mechanism of action of its lead compound, cabozantinib, with respect to its activity against prostate cancer tumors that have metastasized to the bone.

11 Apr 2013

Researchers say testing for BRAF V600E-positive tumors needed for aggressive thyroid cancer

Late stage thyroid cancer patients with aggressive disease may benefit from a genetic test, but experts caution that use of this test in early stage patients is inappropriate because it is unlikely to lead to better outcomes.

11 Apr 2013

Study: microRNA is designed to stop proliferation of prostate cancer cells

The most recent in a series of studies from a team at the UC Davis Comprehensive Cancer Center has shown that a single molecule is at the heart of one of the most basic survival tactics of prostate cancer cells.

10 Apr 2013

Immunotherapy and epigenetics advancements presented by Ludwig at the American Association for Cancer Research

A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at this week’s American Association for Cancer Research (AACR) Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment implications for emerging cancer therapy.

10 Apr 2013

BRAF genetic mutation increases mortality among patients with papillary thyroid cancer

Presence of the genetic mutation BRAF V600E was significantly associated with increased cancer-related death among patients with papillary thyroid cancer (PTC); however, because overall mortality in PTC is low and the association was not independent of tumor characteristics, how to use this information to manage mortality risk in patients with PTC is unclear, according to a study in the April 10 issue of JAMA, a Genomics theme issue.

10 Apr 2013

Tumor News and Research

Study opens new avenues of research to improve care for patients with COPD

Androgen receptors found to be a potential target in breast cancer

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

New research reveals how autophagy keeps neural stem cells to replace damaged brain, nerve cells

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Cellectis CanCELL cell lines enable drug positioning in cancer pathways

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

New research finds HPV plays role in lung cancer in some patients

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

Updated clinical data from phase I study of Ensituximab presented at AACR meeting

Data on PV-10 combination therapy presented at AACR Annual Meeting

Research opens new avenue for treatment of melanoma

Study shows hsa-miR-146a overexpressed in most metastatic tumors

Preclinical study of cabozantinib in prostate cancer bone metastasis model presented at AACR meeting

Researchers say testing for BRAF V600E-positive tumors needed for aggressive thyroid cancer

Study: microRNA is designed to stop proliferation of prostate cancer cells

Immunotherapy and epigenetics advancements presented by Ludwig at the American Association for Cancer Research

BRAF genetic mutation increases mortality among patients with papillary thyroid cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News